Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——
Exelixis logo
ExelixisEXEL
——
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
——

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.62B+226%
Enterprise value$3.53B+275%
P/S15.4×+7.5×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's accrued progress collections and price adjustments?
Arcus Biosciences (RCUS) reported accrued progress collections and price adjustments of $45M in Q1 2026.
How has Arcus Biosciences's accrued progress collections and price adjustments changed year-over-year?
Arcus Biosciences's accrued progress collections and price adjustments decreased by 79.5% year-over-year, from $219M to $45M.
What is the long-term trend for Arcus Biosciences's accrued progress collections and price adjustments?
Over 5 years (2020 to 2025), Arcus Biosciences's accrued progress collections and price adjustments has grown at a -20.2% compound annual growth rate (CAGR), from $132.53M to $43M.